Strategies to deliver peptide drugs to the brain

Molecular Pharmaceutics

Volumn 11, Issue 4, 2014, Pages 1081-1093

  Lalatsa, Aikaterini ^a   Schatzlein, Andreas G ^b,c   Uchegbu, Ijeoma F ^b,c  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c NANOMERICS LTD   (United Kingdom)

Author keywords

blood brain barrier; brain delivery; cell penetrating peptides; intranasal; intravenous; nanoparticles; neurodegenerative diseases; opioid peptides; oral; peptides; receptor mediated endocytosis

Indexed keywords

AMPHOPHILE; ANGIOPEP PEPTIDE; ANGIOTENSIN II; BRAIN PEPTIDE; CELL PENETRATING PEPTIDE; CHITOSAN; CHOLECYSTOKININ OCTAPEPTIDE; INSULIN; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MELANOCORTIN; OXYTOCIN; POLYMER; TRANSFERRIN ANTIBODY; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VASOPRESSIN; NANOPARTICLE; PEPTIDE;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HUMAN; INTESTINE EPITHELIUM; NON INVASIVE PROCEDURE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; AMINO ACID SEQUENCE; ANIMAL; BRAIN; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDES;

EID: 84898008648     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400680d     Document Type: Review

References (143)

1. Lalatsa, A.; Lee, V.; Malkinson, J. P.; Zloh, M.; Schatzlein, A. G.; Uchegbu, I. F. A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain Mol. Pharmaceutics 2012, 9, 1665-80
2. Serrano Lopez, D. R.; Lalatsa, A. Peptide pills for brain diseases? Reality and future perspectives Ther. Delivery 2013, 4, 479-501
3. Van der Walle, C. Peptide and Protein Delivery; Academic Press: New York, 2011.
4. Lax, R. The future of peptide development in the pharmaceutical industry. PharManuf.: Int. Pept. Rev. 2010, http://www.polypeptide.com/assets/002/5188. pdf.
5. Reichert, J. 2010 Report Summary: Development trends for peptide therapeutics: A comprehensive quantitative analysis of peptide therapeutics in clinical development. Peptide Therapeutics Foundation, 2010. www.peptidetherapeutics.org.
6. Strand, F. L. Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders. In Progress in Drug Research: Peptide Transport and Delivery into the Central Nervous System; Prokai, L.; Prokai-Tatrai, K., Eds.; Birkhäuser: Basel, 2003; pp 1-37.
7. Masserini, M. Nanoparticles for Brain Drug Delivery ISRN Biochem. 2013, 10.1155/2013/238428
8. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development NeuroRx 2005, 2, 3-14
9. Zhou, J.; Patel, T. R.; Sirianni, R. W.; Strohbehn, G.; Zheng, M. Q.; Duong, N.; Schafbauer, T.; Huttner, A. J.; Huang, Y.; Carson, R. E.; Zhang, Y.; Sullivan, D. J., Jr.; Piepmeier, J. M.; Saltzman, W. M. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 11751-6
10. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiol. Dis. 2010, 37, 48-57
11. Uchegbu, I. F.; Siew, A. Nanomedicines and nanodiagnostics come of age J. Pharm. Sci. 2013, 102, 305-310
12. Lalatsa, A.; Schatzlein, A. G.; Uchegbu, I. F. Nanostructures Overcoming the Blood-Brain Barrier: Physiological Considerations and Mechanistic Issues. In Nanostructured Biomaterials for Overcoming Biological Barriers; Alonso, M. J.; Csaba, N., Eds.; Royal Society of Chemistry: London, 2012; Chapter 7.1, pp 329-63.
13. Nance, E. A.; Woodworth, G. F.; Sailor, K. A.; Shih, T. Y.; Xu, Q.; Swaminathan, G.; Xiang, D.; Eberhart, C.; Hanes, J. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue Sci. Transl. Med. 2012, 4, 149ra119
14. Mazza, M.; Notman, R.; Anwar, J.; Rodger, A.; Hicks, M.; Parkinson, G.; McCarthy, D.; Daviter, T.; Moger, J.; Garrett, N.; Mead, T.; Briggs, M.; Schatzlein, A. G.; Uchegbu, I. F. Nanofiber-based delivery of therapeutic peptides to the brain ACS Nano 2013, 7, 1016-26
15. Pardridge, W. M. Drug transport across the blood-brain barrier J. Cereb. Blood Flow Metab. 2012, 32, 1959-72
16. Pardridge, W. M.; Boado, R. J. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier Meth. Enzymol. 2012, 503, 269-92
17. Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 1999, 16, 1514-9
18. Lennernas, H.; Lundgren, E. Intestinal and blood-brain drug transport: beyond involvement of a single transport function Drug Discovery Today: Technol. 2004, 1, 417-22
19. Pauletti, G. M.; Okumu, F. W.; Borchardt, R. T. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway Pharm. Res. 1997, 14, 164-8
20. Sorensen, M.; Steenberg, B.; Knipp, G. T.; Wang, W.; Steffansen, B.; Frokjaer, S.; Borchardt, R. T. The effect of beta-turn structure on the permeation of peptides across monolayers of bovine brain microvessel endothelial cells Pharm. Res. 1997, 14, 1341-8
21. Teixido, M.; Belda, I.; Zurita, E.; Llora, X.; Fabre, M.; Vilaro, S.; Albericio, F.; Giralt, E. Evolutionary combinatorial chemistry, a novel tool for SAR studies on peptide transport across the blood-brain barrier. Part 2. Design, synthesis and evaluation of a first generation of peptides J. Peptide Sci. 2005, 11, 789-804
22. Batrakova, E. V.; Vinogradov, S. V.; Robinson, S. M.; Niehoff, M. L.; Banks, W. A.; Kabanov, A. V. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery Bioconjugate Chem. 2005, 16, 793-802
23. Brasnjevic, I.; Steinbusch, H. W.; Schmitz, C.; Martinez-Martinez, P. Delivery of peptide and protein drugs over the blood-brain barrier Prog. Neurobiol. 2009, 87, 212-51
24. Bilsky, E. J.; Egleton, R. D.; Mitchell, S. A.; Palian, M. M.; Davis, P.; Huber, J. D.; Jones, H.; Yamamura, H. I.; Janders, J.; Davis, T. P.; Porreca, F.; Hruby, V. J.; Polt, R. Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability J. Med. Chem. 2000, 43, 2586-90
25. Egleton, R. D.; Mitchell, S. A.; Huber, J. D.; Janders, J.; Stropova, D.; Polt, R.; Yamamura, H. I.; Hruby, V. J.; Davis, T. P. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs Brain Res. 2000, 881, 37-46
26. Lalatsa, A.; Schätchlein, A. G.; Uchegbu, I. F. Drug Delivery across the Blood-brain barrier. In Comprehensive Biotechnology, 2 nd ed.; Moo-Young, M.; Butler, M.; Webb, C.; Moreira, A.; Grodzinski, B.; Cui, Z., Eds.; Elsevier: Amsterdam, 2011; pp 657-68.
27. Cacciatore, I.; Baldassarre, L.; Fornasari, E.; Mollica, A.; Pinnen, F. Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems Oxid. Med. Cell. Longevity 2012, 240146
28. Broadwell, R. D.; Balin, B. J.; Salcman, M. Transcytotic pathway for blood-borne protein through the blood-brain barrier Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 632-6
29. Willingham, M. C.; Hanover, J. A.; Dickson, R. B.; Pastan, I. Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 175-9
30. Abbott, N. J.; Patabendige, A. A.; Dolman, D. E.; Yusof, S. R.; Begley, D. J. Structure and function of the blood-brain barrier Neurobiol. Dis. 2010, 37, 13-25
31. Frank, H. J.; Pardridge, W. M.; Morris, W. L.; Rosenfeld, R. G.; Choi, T. B. Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels Diabetes 1986, 35, 654-61
32. Frank, H. J.; Pardridge, W. M. A direct in vitro demonstration of insulin binding to isolated brain microvessels Diabetes 1981, 30, 757-61
33. van Houten, M.; Posner, B. I.; Kopriwa, B. M.; Brawer, J. R. Insulin-binding sites in the rat brain: in vivo localization to the circumventricular organs by quantitative radioautography Endocrinology 1979, 105, 666-73
34. Duffy, K. R.; Pardridge, W. M.; Rosenfeld, R. G. Human blood-brain barrier insulin-like growth factor receptor Metab., Clin. Exp. 1988, 37, 136-40
35. Fishman, J. B.; Rubin, J. B.; Handrahan, J. V.; Connor, J. R.; Fine, R. E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier J. Neurosci. Res. 1987, 18, 299-304
36. Jefferies, W. A.; Brandon, M. R.; Hunt, S. V.; Williams, A. F.; Gatter, K. C.; Mason, D. Y. Transferrin receptor on endothelium of brain capillaries Nature 1984, 312, 162-3
37. Visser, C. C.; Stevanovic, S.; Heleen Voorwinden, L.; Gaillard, P. J.; Crommelin, D. J.; Danhof, M.; De Boer, A. G. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro J. Drug Targeting 2004, 12, 145-50
38. Demeule, M.; Poirier, J.; Jodoin, J.; Bertrand, Y.; Desrosiers, R. R.; Dagenais, C.; Nguyen, T.; Lanthier, J.; Gabathuler, R.; Kennard, M.; Jefferies, W. A.; Karkan, D.; Tsai, S.; Fenart, L.; Cecchelli, R.; Beliveau, R. High transcytosis of melanotransferrin (P97) across the blood-brain barrier J. Neurochem. 2002, 83, 924-33
39. Banks, W. A.; Farrell, C. L. Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible Am. J. Physiol. 2003, 285, E10-5
40. Pan, W.; Kastin, A. J. TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice Exp. Neurol. 2002, 174, 193-200
41. Pan, W.; Kastin, A. J. Entry of EGF into brain is rapid and saturable Peptides 1999, 20, 1091-8
42. Zlokovic, B. V.; Skundric, D. S.; Segal, M. B.; Lipovac, M. N.; Mackic, J. B.; Davson, H. A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig Exp. Neurol. 1990, 107, 263-70
43. Banks, W. A. Anorectic effects of circulating cytokines: role of the vascular blood-brain barrier Nutrition 2001, 17, 434-7
44. Banks, W. A.; Farr, S. A.; La Scola, M. E.; Morley, J. E. Intravenous human interleukin-1alpha impairs memory processing in mice: dependence on blood-brain barrier transport into posterior division of the septum J. Pharmacol. Exp. Ther. 2001, 299, 536-41
45. Herz, J.; Marschang, P. Coaxing the LDL receptor family into the fold Cell 2003, 112, 289-92
46. Gaillard, P. J.; Brink, A.; de Boer, A. G. Diphtheria toxin receptor-targeted brain drug delivery Int. Congr. Ser. 2005, 1277, 185-198
47. Visser, C. C.; Voorwinden, L. H.; Crommelin, D. J.; Danhof, M.; De Boer, A. G. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells Pharm. Res. 2004, 21, 761-9
48. Banks, W. A.; Kastin, A. J. Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine Peptides 1994, 15, 23-9
49. Lindqvist, A.; Rip, J.; Gaillard, P. J.; Bjorkman, S.; Hammarlund-Udenaes, M. Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study Mol. Pharmaceutics 2013, 10, 1533-41
50. Demeule, M.; Currie, J. C.; Bertrand, Y.; Che, C.; Nguyen, T.; Regina, A.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2 J. Neurochem. 2008, 106, 1534-44
51. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Identification and design of peptides as a new drug delivery system for the brain J. Pharmacol. Exp. Ther. 2008, 324, 1064-72
52. Bertrand, Y.; Currie, J. C.; Demeule, M.; Regina, A.; Che, C.; Abulrob, A.; Fatehi, D.; Sartelet, H.; Gabathuler, R.; Castaigne, J. P.; Stanimirovic, D.; Beliveau, R. Transport characteristics of a novel peptide platform for CNS therapeutics J. Cell. Mol. Med. 2010, 14, 2827-39
53. Herve, F.; Ghinea, N.; Scherrmann, J. M. CNS delivery via adsorptive transcytosis AAPS J. 2008, 10, 455-72
54. Demeule, M.; Regina, A.; Thiot, C.; Che, C.; Beliveau, R.; Castaigne, J. P., ANG2002: A new Angiochem-modified neurotensin with increased brain penetration and analgesic properties (374.11/QQ6). In Society for Neurosciences Annual Meeting; Neuroscience Meeting Planner: San Diego, CA, 2010.
55. Nikolich, K., Taking novel therapeutics to the brain: biologics. In 39th meeting of the Society for Neuroscience; Chicago, 2009.
56. Regina, A.; Demeule, M.; Che, C.; Lavallee, I.; Poirier, J.; Gabathuler, R.; Beliveau, R.; Castaigne, J. P. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2 Br. J. Pharmacol. 2008, 155, 185-97
57. Thomas, F. C.; Taskar, K.; Rudraraju, V.; Goda, S.; Thorsheim, H. R.; Gaasch, J. A.; Mittapalli, R. K.; Palmieri, D.; Steeg, P. S.; Lockman, P. R.; Smith, Q. R. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer Pharm. Res. 2009, 26, 2486-94
58. Malcor, J. D.; Payrot, N.; David, M.; Faucon, A.; Abouzid, K.; Jacquot, G.; Floquet, N.; Debarbieux, F.; Rougon, G.; Martinez, J.; Khrestchatisky, M.; Vlieghe, P.; Lisowski, V. Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting J. Med. Chem. 2012, 55, 2227-41
59. Vlieghe, P.; Khrestchatisky, M. Peptide-based vectors for blood-brain barrier targeting and delivery of drugs to the central nervous system Ther. Delivery 2010, 1, 489-94
60. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: science and market Drug Discovery Today 2010, 15, 40-56
61. Pardridge, W. M. Drug targeting to the brain Pharm. Res. 2007, 24, 1733-1744
62. Pardridge, W. M.; Boado, R. J. Delivery of pharmaceutical agents via the human insulin receptor. United States Patent 2008, 7,388,079.
63. Pang, Z.; Lu, W.; Gao, H.; Hu, K.; Chen, J.; Zhang, C.; Gao, X.; Jiang, X.; Zhu, C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26 J. Controlled Release 2008, 128, 120-7
64. Aktas, Y.; Yemisci, M.; Andrieux, K.; Gursoy, R. N.; Alonso, M. J.; Fernandez-Megia, E.; Novoa-Carballal, R.; Quinoa, E.; Riguera, R.; Sargon, M. F.; Celik, H. H.; Demir, A. S.; Hincal, A. A.; Dalkara, T.; Capan, Y.; Couvreur, P. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 Bioconjugate Chem. 2005, 16, 1503-11
65. Liu, Z.; Gao, X.; Kang, T.; Jiang, M.; Miao, D.; Gu, G.; Hu, Q.; Song, Q.; Yao, L.; Tu, Y.; Chen, H.; Jiang, X.; Chen, J. B6 Peptide-Modified PEG-PLA Nanoparticles for Enhanced Brain Delivery of Neuroprotective Peptide Bioconjugate Chem. 2013, 24, 997-1007
66. Gozes, I.; Divinski, I.; Piltzer, I. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42) BMC Neurosci. 2008, 9, S3
67. van Rooy, I.; Mastrobattista, E.; Storm, G.; Hennink, W. E.; Schiffelers, R. M. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain J. Controlled Release 2011, 150, 30-6
68. Mishra, V.; Mahor, S.; Rawat, A.; Gupta, P. N.; Dubey, P.; Khatri, K.; Vyas, S. P. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles J. Drug Targeting 2006, 14, 45-53
69. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB) Eur. J. Pharm. Biopharm. 2009, 71, 251-6
70. Li, F. Q.; Sempowski, G. D.; McKenna, S. E.; Laskowitz, D. T.; Colton, C. A.; Vitek, M. P. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis J. Pharmacol. Exp. Ther. 2006, 318, 956-65
71. Gaillard, P. J.; de Boer, A. G. A novel opportunity for targeted drug delivery to the brain J. Controlled Release 2006, 116, e60-2
72. Banks, W. A. Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity Curr. Pharm. Des. 2001, 7, 125-33
73. Burgueraa, B.; Couceb, M. E. Leptin access into the brain: A saturated transport mechanism in obesity Physiol. Behav. 2001, 74, 717-20
74. Tosi, G.; Badiali, L.; Ruozi, B.; Vergoni, A. V.; Bondioli, L.; Ferrari, A.; Rivasi, F.; Forni, F.; Vandelli, M. A. Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine (London) 2012, 7, 365-82
75. Morris, M. C.; Deshayes, S.; Heitz, F.; Divita, G. Cell-penetrating peptides: from molecular mechanisms to therapeutics Biol. Cell 2008, 100, 201-17
76. Eiriksdottira, E.; Konateb, K.; Langela, U.; Divitab, G.; Deshayes, S. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion Biochim. Biophys. Acta, Biomembr. 2010, 1798, 1119-28
77. Subrizi, A.; Tuominenb, E.; Bunkera, A.; Rogc, T.; Antopolskya, M.; Urtti, A. Tat(48-60) peptide amino acid sequence is not unique in its cell penetrating properties and cell-surface glycosaminoglycans inhibit its cellular uptake J. Controlled Release 2013, 158, 277-85
78. Rusnati, M.; Coltrini, D.; Oreste, P.; Zoppetti, G.; Albini, A.; Noonan, D.; di Fagagna, F.; Giacca, M.; Presta, M. Interaction of HIV-1 Tat protein with heparin J. Biol. Chem. 1997, 272, 11313-20
79. Liu, Y.; Jones, M.; Hingtgen, C. M.; Bu, G.; Laribee, R. E.; Tanzi, R. E.; Moir, R. D.; Nath, A.; He, J. J. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands Nat. Med. 2000, 6, 1380-7
80. Mitchell, D. J.; Steinman, L.; Kim, D. T.; Fathman, C. G.; Rothbard, J. B. Polyarginine enters cells more efficiently than other polycationic homopolymers J. Pept. Res. 2000, 56, 318-25
81. Erazo-Oliveras, A.; Muthukrishnan, N.; Baker, R.; Wang, T. Y.; Pellois, J. P. Improving the Endosomal Escape of Cell-Penetrating Peptides and Their Cargos: Strategies and Challenges Pharmaceuticals 2012, 5, 1177-209
82. Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; Rothbard, J. B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13003-8
83. Chang, W. P.; Koelsch, G.; Wong, S.; Downs, D.; Da, H.; Weerasena, V.; Gordon, B.; Devasamudram, T.; Bilcer, G.; Ghosh, A. K.; Tang, J. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors J. Neurochem. 2004, 89, 1409-16
84. Drin, G.; Cottin, S.; Blanc, E.; Rees, A. R.; Temsamani, J. Studies on the internalization mechanism of cationic cell-penetrating peptides J. Biol. Chem. 2003, 278, 31192-201
85. Harwig, S. S. L.; Waring, A.; Yang, H. J.; Cho, Y.; Tan, L.; Lehrer, R. I. Intramolecular Disulfide Bonds Enhance the Antimicrobial and Lytic Activities of Protegrins at Physiological Sodium Chloride Concentrations Eur. J. Biochem. 1996, 240, 352-7
86. Chen, J.; Falla, T. J.; Liu, H.; Hurst, M. A.; Fujii, C. A.; Mosca, D. A.; Embree, J. R.; Loury, D. J.; Radel, P. A.; Chang, C. C. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues Biopolymers 2000, 55, 88-98
87. Mangoni, M. E.; Aumelas, A.; Charmet, P.; Roumestand, C.; Chiche, L.; Despaux, E.; Grassy, G.; Calas, B.; Chavanieu, A. Change in membrane permeability induced by protegrin 1: implication of disulphide bridges for pore formation FEBS Lett. 1996, 383, 93-8
88. Adenot, M.; Merida, P.; Lahana, R. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery Chemotherapy 2007, 53, 73-6
89. Rousselle, C.; Clair, P.; Smirnova, M.; Kolesnikov, Y.; Pasternak, G. W.; Gac-Breton, S.; Rees, A. R.; Scherrmann, J. M.; Temsamani, J. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy J. Pharmacol. Exp. Ther. 2003, 306, 371-6
90. Tian, X. H.; Wei, F.; Wang, T. X.; Wang, P.; Lin, X. N.; Wang, J.; Wang, D.; Ren, L. In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain Int. J. Nanomed. 2012, 7, 1031-41
91. Xia, H.; Gao, X.; Gu, G.; Liu, Z.; Hu, Q.; Tu, Y.; Song, Q.; Yao, L.; Pang, Z.; Jiang, X.; Chen, J.; Chen, H. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery Int. J. Pharm. 2012, 436, 840-50
92. Bidwell, G. L., 3rd; Perkins, E.; Hughes, J.; Khan, M.; James, J. R.; Raucher, D. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model PLoS One 2013, 8, e55104
93. Tünnemann, G.; Cardoso, M. C. Cell-Penetrating Peptides Uptake, Toxicity, and Applications. In Membrane-Active peptides: methods and results on structure and function.; Castanho, M., Ed.; IUL Publishers: La Jolla, CA, 2009; pp 331-62.
94. Lalatsa, A.; Garrett, N. L.; Ferrarelli, T.; Moger, J.; Schatzlein, A. G.; Uchegbu, I. F. Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharmaceutics 2012, 9, 1764-74
95. Aliautdin, R. N.; Petrov, V. E.; Ivanov, A. A.; Kreuter, J.; Kharkevich, D. A. Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles Eksp. Klin. Farmakol. 1996, 59, 57-60
96. Lalatsa, A.; Garrett, N.; Moger, J.; Schatzlein, A. G.; Davis, C.; Uchegbu, I. F. Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharmaceutics 2012, 9, 1764-74
97. Das, D.; Lin, S. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration J. Pharm. Sci. 2005, 94, 1343-53
98. Schroeder, U.; Sommerfeld, P.; Sabel, B. A. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier Peptides 1998, 19, 777-80
99. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier J. Drug Targeting 2002, 10, 317-325
100. Popov, M.; Abu Hammad, I.; Bachar, T.; Grinberg, S.; Linder, C.; Stepensky, D.; Heldman, E. Delivery of analgesic peptides to the brain by nano-sized bolaamphiphilic vesicles made of monolayer membranes Eur. J. Pharm. Biopharm. 2013, 85, 381-9
101. Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Gu, G.; Song, Q.; Yao, L.; Hu, Q.; Tu, Y.; Pang, Z.; Chen, H.; Jiang, X.; Gao, X.; Chen, J. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration Biomaterials 2013, 34, 3870-81
102. Yang, D.; Sun, Y. Y.; Lin, X.; Baumann, J. M.; Dunn, R. S.; Lindquist, D. M.; Kuan, C. Y. Intranasal delivery of cell-penetrating anti-NF-κB peptides (Tat-NBD) alleviates infection-sensitized hypoxic-ischemic brain injury Exp. Neurol. 2013, 247, 447-55
103. Liu, L.; Xu, K.; Wang, H.; Tan, P. K.; Fan, W.; Venkatraman, S. S.; Li, L.; Yang, Y. Y. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent Nat. Nanotechnol. 2009, 4, 457-63
104. Ulijn, R. V.; Smith, A. M. Designing peptide based nanomaterials Chem. Soc. Rev. 2008, 37, 664-75
105. Varamini, P.; Toth, I. Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain Front. Pharmacol. 2013, 4, 155
106. Zhang, S.; Marini, D. M.; Hwang, W.; Santoso, S. Design of nanostructured biological materials through self-assembly of peptides and proteins Curr. Opin. Chem. Biol. 2002, 6, 865-71
107. Zhang, S.; Holmes, T.; Lockshin, C.; Rich, A. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 3334-8
108. Paramonov, S. E.; Jun, H. W.; Hartgerink, J. D. Self-assembly of peptide-amphiphile nanofibers: the roles of hydrogen bonding and amphiphilic packing J. Am. Chem. Soc. 2006, 128, 7291-8
109. Cui, H.; Webber, M. J.; Stupp, S. I. Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials Biopolymers 2010, 94, 1-18
110. Sabel, B. A. Drug Targeting system, method of its preparation and its use. United States Patent Application 1997, US 20020034474 A1. PCT/EP1997/003099.
111. Garrett, N. L.; Lalatsa, A.; Uchegbu, I.; Schatzlein, A.; Moger, J. Exploring uptake mechanisms of oral nanomedicines using multimodal nonlinear optical microscopy J. Biophotonics 2012, 5, 458-68
112. Siew, A.; Le, H.; Thiovolet, M.; Gellert, P.; Schatzlein, A.; Uchegbu, I. Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharmaceutics 2012, 9, 14-28
113. Irwin, W. J.; Dwivedi, A. K.; Holbrook, P. A.; Dey, M. J. The effect of cyclodextrins on the stability of peptides in nasal enzymic systems Pharm. Res. 1994, 11, 1698-703
114. Illum, L. Transport of drugs from the nasal cavity to the central nervous system Eur. J. Pharm. Sci 2000, 11, 1-18
115. Reis, C. P.; Veiga, F. J.; Ribeiro, A. J.; Neufeld, R. J.; Damge, C. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response J. Pharm. Sci. 2008, 97, 5290-305
116. Kumar, M.; Pandey, R. S.; Patra, K. C.; Jain, S. K.; Soni, M. L.; Dangi, J. S.; Madan, J. Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery Int. J. Biol. Macromol. 2013, 61, 189-95
117. Ruan, Y.; Yao, L.; Zhang, B.; Zhang, S.; Guo, J. Nanoparticle-mediated delivery of neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of neurotoxin Drug Dev. Ind. Pharm. 2012, 38, 123-8
118. Veronesi, M. C.; Aldouby, Y.; Domb, A. J.; Kubek, M. J. Thyrotropin-releasing hormone d,l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo Brain Res. 2009, 1303, 151-60
119. Kubek, M. J.; Domb, A. J.; Veronesi, M. C. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles Neurotherapeutics 2009, 6, 359-71
120. Suzuki, Y. A.; Lopez, V.; Lönnerdal, B. Mammalian lactoferrin receptors: structure and function Cell. Mol. Life Sci. 2005, 62, 2560-75
121. Lönnerdal, B.; Iyer, S. Lactoferrin: molecular structure and biological function Annu. Rev. Nutr. 1995, 15, 93-110
122. Ji, B.; Maeda, J.; Higuchi, M.; Inoue, K.; Akita, H.; Harashima, H. Pharmacokinetics and brain uptake of lactoferrin in rats Life Sci. 2006, 78, 851e5
123. Gao, X.; Wu, B.; Zhang, Q.; Chen, J.; Zhu, J.; Zhang, W.; Rong, Z.; Chen, H.; Jiang, X. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration J. Controlled Release 2007, 121, 156-67
124. 25-35- treated rats following intranasal administration Eur. J. Pharm. Biopharm. 2012, 80, 368-78
125. Allon Therapeutics, Inc. Announces PSP Clinical Trial Results. ClinicaSpace, 2012. http://www.clinicaspace.com/news-story.aspx?NewsEntityId= 282772&type=email&source=CS-121912 (2nd November).
126. Born, J.; Lange, T.; W., K.; McGregor, G. P.; Bickel, U.; Fehm, H. L. Sniffing neuropeptides: a transnasal approach to the human brain Nat. Neurosci. 2002, 5, 514-6
127. Fehm, H. L.; Smolink, R.; Kern, W.; McGregor, G. P.; Bickel, U.; Born, J. The melonocortin melanocyte-stimulating hormone/adrenocorticotropin (4-10) decreases body fat in humans J. Clin. Endocrinol. Metabol. 2001, 86, 114-8
128. Smolnik, R.; Perras, B.; Molle, M.; Fehm, H. L.; Born, J. Event-related brain potentials and working memory function in healthy humans after single-dose and prolonged intranasal administration of adrenocorticotropin 4-10 and desacetyl-alpha-melanocyte stimulating hormone J Clin. Psychopharmacol. 2000, 20, 445-54
129. Hallschmid, M.; Smolnik, R.; McGregor, G.; Born, J.; Fehm, H. L. Overweight humans are resistant to the weight-reducing effects of melanocortin 4-10 J. Clin. Endocrinol. Metab. 2006, 91, 522-5
130. Derad, I.; Willeke, K.; Pietrowsky, R.; Born, J.; Fehm, H. L. Intranasal angiotensin II directly influences central nervous regulation of blood pressure Am. J. Hypertens. 1998, 11, 971-7
131. Pietrowsky, R.; Struben, C.; Molle, M.; Fehm, H. L.; Born, J. Brain potential changes aft, er intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans Biol. Psychiatry 1996, 39, 332-40
132. Pietrowsky, R.; Thiemann, A.; Kern, W.; Fehm, H. L.; Born, J. A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin Psychoneuroendocrinology 1996, 21, 559-72
133. Kosfeld, M.; Heinrichs, M.; Zak, P. J.; Fischbacher, U.; Fehr, E. Oxytocin increases trust in humans Nature 2005, 435, 673-6
134. Kirsch, P.; Esslinger, C.; Chen, Q.; Mier, D.; Lis, S.; Siddhanti, S.; Gruppe, H.; Mattay, V. S.; Gallhofer, B.; Meyer-Lindenberg, A. Oxytocin modulates neural circuitry for social cognition and fear in humans J. Neurosci. 2005, 25, 11489-93
135. Domes, G.; Heinrichs, M.; Michel, A.; Berger, C.; Herpertz, S. C. Oxytocin improves "mind-reading" in humans Biol. Psychiatry 2007, 61, 731-3
136. Heinrichs, M.; Baurngartner, T.; Kirschbaum, C.; Ehlert, U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress Biol. Psychiatry 2003, 54, 1389-98
137. Labuschange, I.; Phan, K. L.; Wood, A.; Angstadt, M.; Chua, P.; Heinrichs, M.; Stout, J. C.; Nathan, P. J. Oxytocin attenuates amygdala reactivity to fear in generalised social anxiety disorder Neuropsychopharmacology 2010, 35, 2403-13
138. Guastella, A. J.; Einfeld, S. L.; Gray, K. M.; Rinehart, N. J.; Tonge, B. J.; Lambert, T. J.; Hickie, I. B. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders Biol. Psychiatry 2010, 67, 692-4
139. Kern, W.; Born, J.; Schreiber, H.; Fehm, H. L. Central nervous system effects of intranasally administered insulin during euglycemia in men Diabetes 1999, 48, 557-63
140. Benedict, C.; Hallschmid, M.; Hatke, A.; Schultes, B.; Fehm, H. L.; Born, J.; Kern, W. Intranasal insulin improves memory in humans Psychoneuroendocrinology 2004, 29, 1326-34
141. Benedict, C.; Kern, W.; Schultes, B.; Born, J.; Hallschmid, M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of inranasal insulin J. Clin. Endocrinol. Metab. 2008, 93, 1339-44
142. Benedict, C.; Brede, S.; Schioth, H. B.; Lehnert, H.; Schultes, B.; Born, J.; Hallschmid, M. Intranasal serum insulin levels in healthy men Diabetes 2011, 60, 114-8
143. Reger, M. A.; Watson, G. S.; Green, P. S.; Wilkinson, C. W.; Baker, L. D.; Cholerton, B.; Fishel, M. A.; Plymate, S. R.; Breitner, J. C.; DeGroodt, W.; Mehta, P.; Craft, S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD Neurology 2008, 70, 440-8